Learning Objectives

PLATO Primary Efficacy End Point CV Death, MI, or Stroke

TRACER Primary End Point Composite of CV Death, MI, Stroke, Hospitalization for Ischemia, Urgent Revascularization

CHARISMA

Bleeding Trends in PCI

Major Bleeding at Access Sites Pooled Analysis of Bivalirudin Studies

TRITON-TIMI 38

ATLAS ACS 2—TIMI 51 Mortality Benefit With Very-Low-Dose Rivaroxaban in STEMI Patients

TRILOGY-ACS Primary Efficacy End Point to 30 Months (Age < 75 years)

TRILOGY-ACS Subgroup Analysis in Patients With Non-STEMI ACS

ACUITY Intraprocedural Thrombotic Events (IPTE*)

Intraprocedural Stent Thrombosis During PCI

EUROMAX Stent Thrombosis With Bivalirudin Treatment

RAPID Patients With Residual Reactivity Over Time

CHAMPION PLATFORM

CHAMPION PCI

CHAMPION PHOENIX Primary Efficacy Outcomes at 48 Hours, MITT

Third Universal Definition of MI

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)